Samil Pharmaceutical

삼일제약 · 000520

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$111.4M (₩153.8B)

Overview

Samil Pharmaceutical makes medicines for everyday use, including a children's ibuprofen syrup and eye-care and digestive products, as well as prescription drugs focused on ophthalmology, liver disease, and gastrointestinal conditions.

Its products reach patients through hospitals, clinics, and pharmacies across South Korea. Listed on KOSPI, Korea's main stock exchange, the company earns revenue both from drugs it develops and manufactures itself, including generics and improved reformulations, and from original branded medicines it imports and distributes exclusively in Korea.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$152.4M

▼ −4.3% YoY

Operating profit · FY2025

−US$16.1M

Turned to loss

Net income · FY2025

−US$25.1M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$142.3M(₩196.3B)	US$159.2M(₩219.7B)	US$152.4M(₩210.3B)
Operating profit	US$4.7M(₩6.5B)	US$81.9K(₩113M)	−US$16.1M(−₩22.2B)
Net income	US$1.2M(₩1.7B)	−US$4.1M(−₩5.6B)	−US$25.1M(−₩34.7B)

Revenue

FY2023US$142.3M
FY2024US$159.2M
FY2025US$152.4M

Operating profit

FY2023US$4.7M
FY2024US$81.9K
FY2025−US$16.1M

Net income

FY2023US$1.2M
FY2024−US$4.1M
FY2025−US$25.1M

Key ratios (FY2025)

ROE

-26.0%

Debt/Eq

178.8%

Op. margin

-10.6%

Net margin

-16.5%

Rev. YoY

▼ −4.3%

Why it matters

The company operates a contract manufacturing facility in Vietnam built to international pharmaceutical quality standards, focused on ophthalmic products for global customers.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?